SpringWorks Therapeutics, Inc.

NasdaqGS:SWTX Lagerbericht

Marktkapitalisierung: US$3.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

SpringWorks Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Für SpringWorks Therapeutics wird ein Gewinn- und Umsatzwachstum von 62.1% bzw. 28.3% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 63.9% pro Jahr steigen soll.

Wichtige Informationen

62.1%

Wachstumsrate der Gewinne

63.92%

EPS-Wachstumsrate

Biotechs Gewinnwachstum25.4%
Wachstumsrate der Einnahmen28.3%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert01 Jul 2025

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Seeking Alpha • Apr 29

SpringWorks: Acquired By Merck KGaA Based On Rare Tumor Targeting Drugs Like OGSIVEO

Summary Merck KGaA agreed to acquire SpringWorks Therapeutics for $47 per share in cash or for $3.9 billion; the acquisition brings in drugs of OGSIVEO and GOMEKLI to big pharma's pipeline. Expansion opportunities for OGSIVEO include potential European approval for desmoid tumors and trials for relapsed/refractory ovarian granulosa cell tumors. GOMEKLI's approval for NF1-PN patients and ongoing European review further enhance SpringWorks' pipeline value. GOMEKLI is also being explored in a phase 1/2 open-label study to treat pediatric and adult patients with low-grade gliomas. Read the full article on Seeking Alpha
Analyseartikel • Mar 12

SpringWorks Therapeutics, Inc.'s (NASDAQ:SWTX) Shares Climb 26% But Its Business Is Yet to Catch Up

The SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX ) share price has done very well over the last month, posting an...
Seeking Alpha • Mar 11

SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz

Summary SpringWorks Therapeutics portfolio features Ogsiveo for desmoid tumors and Gomekli for NF1‑plexiform neurofibromas. In fact, Ogsiveo’s revenues alone reached $172 million in 2024, supported by orphan drug designations in the US and EU. Similarly, Gomekli is the first FDA-approved MEK inhibitor for NF1‑plexiform neurofibromas, which targets both adults and children. SpringWorks is also working on new potential indications for its IP portfolio while running additional trials and even attracting M&A interest from larger players. In my view, SWTX stock’s valuation has a bit of premium embedded in it, but it looks well deserved. In fact, I believe it’s a good speculative “Buy” at these levels. Read the full article on Seeking Alpha
Seeking Alpha • Jan 13

SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate

Summary SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024, and potential EMA approval if it could boost sales further. Mirdametinib, a MEK inhibitor for NF1-PN, has a PDUFA date of February 28th of 2025, and could unlock significant shareholder value if approved. Results from phase 1b study using brimarafenib to treat patients with MAPK mutant solid tumors are expected to be released in the 2nd half of 2025. The company has $498 million in cash as of September 30th of 2024, which is sufficient to fund its operations into the first half of 2026. Read the full article on Seeking Alpha
Seeking Alpha • Dec 31

SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great

Summary SpringWorks Therapeutics shows promising growth with their first approved drug and an imminent second approval for mirdametinib in NF1 treatment. SWTX's financials reveal strong cash reserves and growing sales, though they remain unprofitable, with a net loss of $53.5 million in Q3 2024. Strengths include sustained sales growth and potential back-to-back drug approvals, but risks involve market competition and aggressive goal setting. Despite current valuation concerns, SWTX's fundamentals and potential sales growth justify a "Buy" sentiment for the stock. Read the full article on Seeking Alpha
Seeking Alpha • Dec 15

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

Summary Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics. SpringWorks Therapeutics has promising data with multiple launches planned for next year. Tarsus Pharmaceuticals' lead drug shows strong launch metrics, suggesting significant upside potential despite its current market cap. Read the full article on Seeking Alpha
Analyseartikel • Nov 15

Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results

It's been a pretty great week for SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX ) shareholders, with its shares surging...
Seeking Alpha • Nov 04

SpringWorks Therapeutics Merits A Speculative Buy

Summary Since we last visited SpringWorks Therapeutics, Inc. in the summer of 2023, the company has garnered its first FDA approval. That drug has seen encouraging initial sales, and management recently submitted a marketing application for a second candidate. The stock has pulled back recently, even as SpringWorks has funding to get the company to profitability in the years ahead. An updated analysis around SpringWorks Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Aug 07

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

Summary SWTX's market confidence has increased post-launch, with $40.2 million in product revenue and $19.5 million in collaboration revenue in the first quarter. Nirogacestat approval for desmoid tumors and potential approval for mirdametinib in 2025 position SWTX well for growth. SWTX's strong commercial execution and expanding product portfolio indicate the potential for profitability and market appreciation. Read the full article on Seeking Alpha
Analyseartikel • May 11

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX ) shareholders will have a reason to smile today, with the analysts making...
Analyseartikel • May 03

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Apr 25

SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear

Summary SpringWorks Therapeutics has received FDA approval for Nirogacestat, marking its entry into the commercial stage biotech industry. The company is now facing the challenge of successfully commercializing its therapy. With rapidly growing losses and its hefty market cap SpringWorks Therapeutics is a "Hold". Read the full article on Seeking Alpha
Seeking Alpha • Apr 19

SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners

Summary SpringWorks Therapeutics received FDA approval for its oral gamma secretase inhibitor Ogsiveo for the treatment of desmoid tumors in November last year. Ogsiveo is the first therapy approved for desmoid tumors, with a market opportunity estimated at $2.2 billion. Sales in Q4 2023 were just $5m, however, while net loss was $325m. Ogsiveo could win approval in Europe and also in a new indication Ovarian Granulosa Cell Tumors, opening up larger markets. A second candidate, mirdametinib, may be on track for approval in the rare disease NF-1, and is being evaluated in oncology settings also - as is nirogacestat (Ogsiveo). With more early stage programs, and multiple catalysts in play, some may feel SpringWorks's shares - up over 70% on a 12-months basis - can realise further upside. There is alot of uncertainty, however, which I why I maintain a "hold" rating. Read the full article on Seeking Alpha
Analyseartikel • Sep 20

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analyseartikel • Jun 07

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Feb 22

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Nov 09

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:SWTX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202769376N/AN/A2
12/31/2026572-86N/AN/A3
12/31/2025320-309N/AN/A2
3/31/2025220-254-186-165N/A
12/31/2024192-258-196-176N/A
9/30/2024135-275-221-209N/A
6/30/202486-301-248-234N/A
3/31/202426-339-245-240N/A
12/31/20235-325-230-223N/A
9/30/2023N/A-305-226-214N/A
6/30/2023N/A-298-195-183N/A
3/31/2023N/A-289-185-175N/A
12/31/2022N/A-277-172-162N/A
9/30/2022N/A-259-164-154N/A
6/30/2022N/A-228-168-161N/A
3/31/2022N/A-206-160-155N/A
12/31/2021N/A-174-130-128N/A
9/30/202135-107-67-66N/A
6/30/202135-87-55-54N/A
3/31/202135-60-37-37N/A
12/31/202035-46-33-32N/A
9/30/2020N/A-73-64-63N/A
6/30/2020N/A-68-60-60N/A
3/31/2020N/A-62-57-57N/A
12/31/2019N/A-51-48-47N/A
9/30/2019N/A-41-35-34N/A
6/30/2019N/A-29-31-30N/A
3/31/2019N/A-18-20-19N/A
12/31/2018N/A-18N/A-14N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SWTX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.9%).

Ertrag vs. Markt: SWTX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: SWTX wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: SWTXDie Einnahmen des Unternehmens (28.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (13% pro Jahr).

Hohe Wachstumseinnahmen: SWTXDie Einnahmen des Unternehmens (28.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SWTX in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2025/07/02 09:14
Aktienkurs zum Tagesende2025/06/30 00:00
Gewinne2025/03/31
Jährliche Einnahmen2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

SpringWorks Therapeutics, Inc. wird von 4 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Cory KasimovEvercore ISI
Corinne JohnsonGoldman Sachs
Michael SchmidtGuggenheim Securities, LLC